Скачать с ютуб 脑栓塞的溶栓药物有哪些 吕尤 徐州矿务集团总医院 в хорошем качестве

脑栓塞的溶栓药物有哪些 吕尤 徐州矿务集团总医院

脑栓塞的溶栓药物有哪些 吕尤 徐州矿务集团总医院 溶栓药是促进纤维蛋白溶解而溶解血栓的药。脑栓塞的溶栓药物有以下几种：1、链激酶(SK):本品是一种从C组溶血性链球菌产生的蛋白激酶提纯的制剂,现已可用基因工程制备。其作用是与纤溶酶原结合成复合物,裂解其560精氨酸及561缬氨酸肽链,形成纤溶酶而激活纤溶。2、酰基纤溶酶原链激酶活化剂复合物(APSAC):现常用的复合物制剂是酰基纤溶酶原链激酶活化剂复合物(APSAC),酰基化的部位是在链激酶的丝氨酸酶区。APSAC不具活性,但注入血液后,在血栓的纤维蛋白上,酰基被水解,丝氨酸蛋白酶区暴露,激活纤溶酶原。3、尿激酶(UK):临床上所用的尿激酶是从尿中提取,UK制品中含有高分子量UK(相对分子质量54000)及低分子量UK(相对分子量33000),后者能激活全身性纤溶的作用,容易引起出血。故质量高的UK制剂中高分子量的UK含量应在90%以上。4、组织型纤溶酶原活化剂(t-PA):以往本品是从黑色素细胞瘤培养液中提取,产量很低。现已用基因工程大量制备,t-PA的优点是对纤维蛋白血栓有特异性的选择性溶栓作用,而全身性溶栓作用小,不会引起高纤维溶酶血症。 What are the thrombolytic drugs for cerebral embolism Thrombolytic agents are drugs that promote fibrinolysis and dissolve thrombus. There are several thrombolytic drugs for cerebral embolism: 1. Streptokinase (SK): This product is a preparation purified from protein kinase produced by group C hemolytic streptococcus, Now it can be prepared by genetic engineering. Its function is to synthesize complex with plasminogen, The 560 arginine and 561 valine peptide chains were cleaved, To form plasmin and activate fibrinolysis. 2. Acyl plasminogen streptokinase activator complex (APSAC): the most commonly used complex preparation is acyl plasminogen streptokinase activator complex (APSAC), The site of acylation is in serinase region of streptokinase. APSAC is not active, But after the injection, On fibrin of thrombus, Acyl groups are hydrolyzed, Exposure of serine protease region, Activate plasminogen. 3. Urokinase (UK): urokinase is extracted from urine, UK products contain high molecular weight UK (relative molecular weight 54000) and low molecular weight UK (relative molecular weight 33000), The latter can activate systemic fibrinolysis, Easy to cause bleeding. Therefore, the content of high molecular weight UK in high quality UK preparation should be more than 90%. 4. Tissue plasminogen activator (t-PA): in the past, this product was extracted from the culture medium of melanoma, The output is very low. It has been prepared in large quantities by genetic engineering, The advantage of t-PA is that it has a specific selective thrombolytic effect on fibrin thrombus, However, systemic thrombolysis has little effect, It will not cause hyperfibrinolysis.